Intra-Cellular Therapies, Inc.
(NASDAQ : ITCI)

( )
ITCI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-1.37%203.171.3%$753.07m
GILDGilead Sciences, Inc.
0.05%63.470.9%$381.71m
CELGCelgene Corporation
0.04%95.261.3%$343.41m
BIIBBiogen Inc.
-1.88%231.281.3%$298.49m
ILMNIllumina, Inc.
-1.39%284.653.5%$294.02m
VRTXVertex Pharmaceuticals Incorporated
-1.80%183.721.9%$258.56m
ALXNAlexion Pharmaceuticals, Inc.
-1.11%111.432.0%$246.10m
EXASExact Sciences Corporation
1.10%119.4624.1%$244.15m
REGNRegeneron Pharmaceuticals, Inc.
-0.79%296.032.6%$213.21m
AAgilent Technologies, Inc.
-0.86%71.131.6%$201.92m
SRPTSarepta Therapeutics, Inc.
-15.16%102.0714.7%$172.24m
INCYIncyte Corporation
-0.50%84.102.5%$98.20m
BMRNBioMarin Pharmaceutical Inc.
-1.16%76.514.3%$93.30m
GHDXGenomic Health, Inc.
-0.49%73.861.8%$87.01m
SGENSeattle Genetics, Inc.
-0.96%78.636.5%$81.93m

Company Profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.